丝裂原活化蛋白激酶10及整合素α6预测声门上型喉癌对TPF诱导化疗方案的敏感性  

Expression of MAPK10 and Itga6 in laryngeal carcinoma can predict the sensitivity to TPF chemotherapy

作　　者：杨光[1,2] 时倩 房居高[1] 廉猛[1] 王茹[1] 马泓智[1] 冯凌[1] 王宇[2] 刘红刚 YANG Guang;SHI Qian;FANG Jugao;LIAN Meng;WANG Ru;MA Hongzhi;FENG Ling;WANG Yu;LIU Honggang(Department of Otolaryngology Head and Neck Surgery,Beijing Tongren Hospital,Capital Medical University,Key Laboratory of Otolaryngology Head and Neck Surgery（Capital Medical University）,Ministry of Education,Beijing,100730,China;Department of Otolaryngology Head and Neck Surgery,No.263 Department of Clinical,Army General Hospital,Beijing,101100,China;Department of Pathology,Beijing Tongren Hospital,Capital Medical University,Beijing,100730,China)

机构地区：[1]首都医科大学附属北京同仁医院耳鼻咽喉头颈外科、耳鼻咽喉头颈科学教育部重点实验室(首都医科大学),北京100730 [2]陆军总医院二六三临床部耳鼻咽喉头颈外科,北京101100 [3]首都医科大学附属北京同仁医院病理科,北京100730

出　　处：《中国耳鼻咽喉头颈外科》2018年第9期473-477,共5页Chinese Archives of Otolaryngology-Head and Neck Surgery

摘　　要：目的预测丝裂原活化蛋白激酶(mitogenactivated protein kinase10,MAPK10)及整合素α6(Integrinα6)在声门上型喉癌中对紫杉醇+顺铂+5氟尿嘧啶(TPF)诱导化疗方案敏感性的价值。方法将2014年9月~2016年9月在我科治疗的57例声门上型喉鳞状细胞癌患者纳入研究。所有患者接受2个周期的TPF方案诱导化疗,并将患者按照疗效分为化疗敏感组和化疗耐受组。采用免疫组化对所有患者病理标本中MAPK10及Itga6表达进行检测,并分析mRNA与蛋白表达一致性,以及蛋白表达与患者临床病理资料之间的关系。结果 MAPK10在敏感组中表达率较高为90.48%,Itga6在耐受组中表达率较高为83.33%,两组之间差异有统计学意义。MAPK10在耐受组中表达水平低于敏感组,Itga6 mRNA高于敏感组,差异有统计学意义。一致性检验表明MAPK10及Itga6在耐受组之中mRNA表达及与蛋白表达一致性较高。MAPK10及Itga6的表达与年龄、性别、肿瘤直径无关;MAPK10的表达与临床分期、病理分级相关,阳性率越低患者病情越重。Spearman等级相关分析结果表明MAPK10与Itga6表达水平之间存在负相关关系,在敏感组喉癌组织中MAPK10与Itga6表达水平之间同样存在负相关关系。结论 MAPK10在对化疗耐受的喉癌组织中表达下调,而Itga6表达上调,且表达水平之间存在负相关关系,因此有可能成为喉癌诱导化疗疗效预测的分子标志物。OBJECTIVE To study the value of MAPK10 and Itga6 in lar yngeal carcinoma and its inf luence on the sensitivity to paclitaxel, cisplatin and 5-fluorouracil（TPF） chemotherapy. METHODS A total of 57 patients with supraglottic squamous cell carcinoma, who were treated with 2 cycles of TPF induction chemotherapy in our hospital, were enrolled in this study and divided into groups with chemotherapy resistance or chemotherapy sensitivity. The expression of mRNA and protein of MAPK10 and Itga6 in tumor tissues were evaluated by immunohistochemistry, the consistency of mRNA and protein was tested, and the relation with the clinicopathological features was analyzed. RESULTSThe positive rates of MAPK10 in the tumor tissues of the sensitive group were significantly higher than those of the resistant group, while Itga6 was significantly higher in the resistant group. The mRNA levels of MAPK10 were significantly lower in the resistant group than those in the sensitive group, while that of Itga6 was significantly higher in the resistant group. The protein expression of MAPK10 and Itga6 was consistent with their mRNA expression. The expression of MAPK10 and Itga6 were not correlated with age, gender and tumor diameter（P〉0.05）, but negatively cor related with clinical stage, pathological g rading. The negative correlations between MAPK10 and Itga6 i n sensit ive t u mor t issues were fou nd by Spea r ma n assay, and which were also negative in the resistant t u mor t issues. CONCLUSION T he M A PK10 were down-reg ulated, while Itga6 was up-reg ulated in the chemo-resistant laryngeal carcinoma, and the expression levels were correlated with each other, which might be important biomarkers of chemotherapy in the future.

关 键 词：喉肿瘤 丝裂原活化蛋白激酶10 整合素Α6 诱导化疗 耐药 

分 类 号：R739.65[医药卫生—肿瘤]